Spots Global Cancer Trial Database for iberdomide
Every month we try and update this database with for iberdomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." | NCT04998786 | Multiple Myelom... | Ixazomib Iberdomide Dexamethasone O... | 70 Years - | Nantes University Hospital | |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | NCT05289492 | Multiple Myelom... | EOS884448 Iberdomide Dexamethasone | 18 Years - | iTeos Therapeutics | |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | NCT04884035 | Lymphoma, B-Cel... | CC-220 Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone CC-99282 Polatuzumab ved... Rituximab | 18 Years - | Celgene | |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | NCT06232044 | Recurrent Multi... Refractory Mult... | Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | NCT05434689 | Multiple Myelom... | Iberdomide Daratumumab Dexamethasone Carfilzomib | 19 Years - | University of Alabama at Birmingham | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | NCT06216158 | Multiple Myelom... | Iberdomide Isatuximab Dexamethasone | 18 Years - | University of Heidelberg Medical Center | |
| Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | NCT05527340 | Multiple Myelom... | Iberdomide Dexamethasone Daratumumab | 18 Years - | PETHEMA Foundation | |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." | NCT04998786 | Multiple Myelom... | Ixazomib Iberdomide Dexamethasone O... | 70 Years - | Nantes University Hospital | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | NCT06215118 | Multiple Myelom... | Elranatamab Iberdomide | 18 Years - | Pfizer | |
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | NCT05434689 | Multiple Myelom... | Iberdomide Daratumumab Dexamethasone Carfilzomib | 19 Years - | University of Alabama at Birmingham | |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | NCT05199311 | Multiple Myelom... | Carfilzomib Iberdomide Oral Dexamethas... | 18 Years - | Hackensack Meridian Health | |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | NCT05896228 | Refractory Mult... Relapsed Multip... | Iberdomide Carfilzomib Daratumumab Dexamethasone Acetaminophen Diphenhydramine Montelukast | 18 Years - 75 Years | University of Miami | |
| Iberdomide Maintenance Therapy in Patients With Multiple Myeloma | NCT05177536 | Multiple Myelom... | Iberdomide | 18 Years - | University of Nebraska | |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | NCT05896228 | Refractory Mult... Relapsed Multip... | Iberdomide Carfilzomib Daratumumab Dexamethasone Acetaminophen Diphenhydramine Montelukast | 18 Years - 75 Years | University of Miami | |
| Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | NCT05354557 | Multiple Myelom... | Iberdomide | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients | NCT05272826 | Multiple Myelom... | Iberdomide Bortezomib Dexamethasone Isatuximab | 65 Years - | Canadian Myeloma Research Group | |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | NCT06179888 | Multiple Myelom... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Iberdomide Magnetic Resona... Patient Monitor... Positron Emissi... Skeletal Survey... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | NCT05289492 | Multiple Myelom... | EOS884448 Iberdomide Dexamethasone | 18 Years - | iTeos Therapeutics | |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | NCT06348108 | Multiple Myelom... Refractory Mult... Relapsed Multip... | Talquetamab Iberdomide Dexamethasone Bone Marrow Bio... | 18 Years - | University of California, San Francisco | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | NCT06232044 | Recurrent Multi... Refractory Mult... | Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | NCT04884035 | Lymphoma, B-Cel... | CC-220 Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone CC-99282 Polatuzumab ved... Rituximab | 18 Years - | Celgene | |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | NCT05199311 | Multiple Myelom... | Carfilzomib Iberdomide Oral Dexamethas... | 18 Years - | Hackensack Meridian Health | |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | NCT05527340 | Multiple Myelom... | Iberdomide Dexamethasone Daratumumab | 18 Years - | PETHEMA Foundation | |
| Iberdomide Maintenance Therapy in Patients With Multiple Myeloma | NCT05177536 | Multiple Myelom... | Iberdomide | 18 Years - | University of Nebraska | |
| Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | NCT05354557 | Multiple Myelom... | Iberdomide | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
